iShares Genomics Immunology and Healthcare ETFIDNA

The iShares Genomics Immunology and Healthcare ETF (IDNA) is a thematic wrapper designed to give investors exposure to the genomics and immunology sectors through a single ticker, but the fund’s glossy pitch masks a reality that’s more mundane than miraculous. IDNA is not a biotech miracle machine; it’s an exchange-traded fund that holds a basket of companies engaged in gene sequencing, immunotherapy, and related fields, and it charges 0.40% annually for the privilege of owning them. The fund’s mandate is clear: provide exposure to the genomics and immunology revolution. What’s less clear is how many of its holdings are actually revolutionising anything versus merely hoping to.

The fund’s top holdings and concentration levels aren’t disclosed in the evidence rail, but the issuer’s marketing materials and product pages repeatedly emphasise the “potential growth and innovation” of the sector. The imagery used-think sleek machinery and futuristic labs-suggests a high-tech engine of progress, while the actual holdings are a mix of startups, mid-caps, and established players all betting on the next big breakthrough. The fund’s AUM and liquidity figures aren’t provided in the evidence, but the issuer’s status as the world’s largest ETF provider suggests the fund is at least liquid enough for institutional use. For retail investors, the fee is the only certainty: 40 basis points per year, deducted regardless of how the basket performs.

The fund’s tracking method is standard for an ETF: it aims to replicate the performance of an index composed of genomics and immunology companies. The issuer’s product pages claim the ETF “captures AI’s potential growth and innovation through the ease and convenience of an ETF,” which is a creative stretch given that IDNA’s mandate is genomics and immunology, not AI. The evidence rail also notes that most protections provided by the UK regulatory system do not apply to iShares products, and compensation will not be available under the UK Financial Services Compensation Scheme in the event of default. This is not a selling point, but it’s worth knowing.

The SEC EDGAR filings for IDNA confirm the fund’s existence and structure, but they don’t provide granular details about the holdings, performance, or concentration risk. The fund’s official iShares pages and Nasdaq listing confirm its ticker and exchange, but they don’t offer a breakdown of the basket or its recent performance. The FINRA Fund Analyzer can provide some insight into fees and expenses, but it doesn’t reveal the fund’s holdings or how the basket has performed relative to its mandate.

The fund’s mandate is to provide exposure to the genomics and immunology sectors, but the evidence rail doesn’t provide a current snapshot of the basket’s composition or performance. The issuer’s marketing suggests a high-growth, high-innovation story, but the reality is a fee-extracting wrapper around a sector that’s as volatile as it is promising. If you’re buying IDNA, you’re not just betting on science; you’re also betting that the issuer’s fee doesn’t erode your returns faster than the sector can deliver.